According to a recent assessment by Future Market Insights (FMI), the opioid analgesics market is slated to expand at a 5.2% CAGR, attaining US$ 43.3 billion in 2023. Soaring demand for post-surgery pain management and advancements in drug formulations to reduce analgesic side effects are predicted to propel sales of opioid analgesics over the forecast period.
Morphin sales are expected to command 13% of the overall opioid analgesics market share, with a market valuation of US$ 72.0 billion by 2033, according to FMI.
The Opioid Analgesics Key Determinants - Creating Hype
Opioid analgesics are ideal for pain management and palliative care due to their convenience and efficacy. However, to reduce the risk of addiction and overuse, definite restrictions on opioid sales are in place.
As a result, manufacturers are trying to enhance their product offerings by investing in research and development to develop milder and less addictive drugs. It points to lucrative market growth opportunities for key opioid analgesics manufacturers.
The Valuable Opportunities for Market Makers in the Couple of Years
On the other hand, many people believe that smaller doses of opioids are ineffective in alleviating severe pain. These patients require more drugs to relieve their pain, which inevitably leads to opioid tolerance and, in some cases, addiction to these drugs.
One of the primary opportunities for opioid analgesic manufacturers in the opioid drugs market is expected to be the commercialization of opioid-tolerant drugs. It helps to reduce the side effects caused by or associated with high opioid drug consumption, which is estimated to boost sales of opioid analgesics in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Rising Prevalence of Opioid Addiction May Harm its Sales
The primary factors limiting global market growth are the unavailability of opioids in emerging markets and the side effects associated with these drugs. Aside from that, the escalating magnitude of abusive opioids and their misuse impedes global market growth.
Furthermore, chronic opioid side effects pose a significant barrier to market growth. Due to the increased abuse of addictive opioids, physicians have scaled back their pain management prescriptions, decreasing global sales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 5.2% |
| Market Valuation (2023) | US$ 43.3 billion |
| Market Valuation (2033) | US$ 72.0 billion |
According to the drug class, oxycodone is expected to account for 19.1% of the global market. Oxycodone is one of the most potent pain relievers on the market. The medication relieves pain and allows patients to go about their daily activities.
Previously, oxycodone was not widely used due to a lack of knowledge about the constituents and the high cost of drugs. The rising awareness about the benefits of oxycodone, such as increased bioavailability, is encouraging the drug's use.
Global Market by Indication
Due to the rise in surgical procedures and the incidence of associated post-operative pain, the indication of surgical pain is expected to account for 45.9% of the opioid analgesics market share.
Opioid analgesics are used as an effective treatment for pain management following an operation or surgery. Over the forecast period, increased adoption of medications for pain management and relief is expected to drive demand for opioid analgesics.
Global Market by Route of Administration
Hospital pharmacies are expected to account for 33.4% of the total market share. Hospitals are leading care facilities with a large presence of well-trained staff and professionals who assist patients in receiving effective treatment. Adoption of prescribed therapy in clinics and hospitals aids in physician-supervised drug delivery. It is one of the primary factors driving sales of opioid analgesics through hospital pharmacies.
Principal Consultant
| Countries | Forecast Share Between 2023 to 2033 |
|---|---|
| United States | 41.9% |
| Germany | 5.7% |
| Japan | 4.2% |
| Countries | Forecast CAGR Between 2023 to 2033 |
|---|---|
| Australia | 4% |
| China | 7.7% |
| India | 5.3% |
| United Kingdom | 4.3% |
The United States is expected to dominate the global market, accounting for 41.9% of the global market. The rising prevalence of chronic illnesses, as well as the growing adoption of opioid analgesics as pain relievers, is expected to continue to boost sales of opioid analgesics.
Key opioid analgesic manufacturers in the United States are focusing on launching new products to comply with updated regulatory procedures. Furthermore, government-led investments in clinical research are estimated to enable the country to maintain its dominance over the forecast period.
In Germany, sales of opioid analgesics are expected to record a 3.8% CAGR, reaching a valuation of US$ 2.2 billion in 2023. Germany is estimated to secure a CAGR of 5.7% in the global market by 2033.
Adoption of opioid maintenance treatment (OMT) for treating opioid dependence (O.D.), increased use of non-abusive opioids, and favorable reimbursement programs offered by German regulatory bodies regarding awareness of palliative care are key factors driving sales of opioid analgesics in Germany.
The United Kingdom is expected to lead the European market, with sales increasing at a 4.3% CAGR during the forecast period.
The healthcare system in the United Kingdom is well-known and universal, with significant government funding. It is widely regarded as having one of the most thriving healthcare systems in the world.
The United Kingdom is the third leading global market, and this position is expected to be maintained throughout the forecast period. Furthermore, the presence of several key players, expanding pipeline drugs, and increasing research efforts create lucrative global market opportunities in the United Kingdom.
China is expected to lead the East Asian market in 2023, accounting for a CAGR of 7.7% in the global market share. Due to the increasing use of large amounts of opioids for pain management and its extensive manufacturing capacity, China dominates the East Asian market.
Due to rapid productivity and large-scale capital investments in the healthcare sector, China is the world's second-largest pharmaceutical market.
India is anticipated to account for 35.4% of the South Asian market for opioid analgesics, with sales increasing at a steady 5.3% CAGR.
Due to the nation's rising need for opioid analgesics, small and large pharmaceutical companies in India actively fund research and development. Many innovative drugs in the funnel are mostly finished and are estimated to be accessible to patients soon.
Clinical trials for opioid analgesics are made possible by government-funded healthcare and pharmaceutical institutions in India. In the upcoming years, the increase in research activities underway in India is anticipated to fuel the global market.
With the addition of two complementary development initiatives, the acquisition of Metys expands Novaremed's pipeline of novel, non-opioid development candidates for chronic pain indications.
With the addition of chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on excruciating diabetic peripheral neuropathy, Novaremed's pipeline expansion enables it to target a wider segment of neuropathic pain indications (PDPN).
The company announced that Bristol Myers Squibb acquired Turning Point Therapeutics, Inc. in an all-cash deal. Turning Point is now a fully owned subsidiary of Bristol Myers Squibb after the acquisition was finalized, and shares of Turning Point no longer trade on the NASDAQ Global Select Market.
AntalGenics, a Spanish startup, created novel molecules to treat chronic pain. The startup is looking into two molecules, AG1529 and AG1531, to treat osteoarthritis pain and psoriatic pruritus. Additionally, the startup creates cosmetic active ingredients for skin and scalp sensitivity.
At in-cosmetics Virtual 2020, AntalGenics is estimated to introduce two of its cutting-edge neuro cosmetic ingredients: Capsisilence, which promotes a healthy scalp, and Calmapsin, which lessens the signs of sensitive skin.
A drug to mimic the effects of morphine without the negative side effects is being developed by the French startup InnoPain. The analgesic effect of morphine is produced by an interaction between the startup's lead candidate, TREK-1, and the -opioid receptor (OR). The startup is also working on RNE28, a new oral and intravenous analgesic medication class.
The pharmaceutical company Neumentum has raised US$ 6 million in a Series A funding round by selling Series A Convertible Preferred Stock. Momentum is committed to revolutionizing how acute and chronic pain is treated without using opioids. The sole placement agent for the financing was Brookline Capital Markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Crucial players emphasize product portfolio expansion by launching new and updated products in the emerging market. Players in the market for opioid analgesics are anticipated to benefit from product approvals, agreements, partnerships, facility expansion, and strategic collaborations to achieve a competitive advantage.
Pfizer Inc., Abbott Laboratories, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., and Sanofi S.A. are some of the significant players operating in the market for opioid analgesics.
Recent Developments in the Global Market are:
The FDA approved the new drug application Allergan PLC submitted in January 2020. The application was made by a business called DURYSTA for the Food and Drug Administration. It is the first of its kind and aims to lower intraocular pressure by giving sustained-release, biodegradable medication. Due to open-angle glaucoma and ocular hypertension (OHT), this is possible.
The FDA disclosed that the Prescription Drug User Fee Act (PDUFA) may come into effect on December 1st, 2019, at Veritas Pharma Inc. In 2020, Daiichi Sankyo declared its plan to collaborate with Ultragenyx Pharmaceutical to enhance research.
| Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market in 2023 is valued at US$ 43.3 billion.
Hospital pharmacies are expected to account for a market share of 33.4%.
The market will register a 5.2% CAGR until 2033.
By 2033, the market will reach US$ 72.0 billion.
The Chinese market is likely to register a CAGR of 7.7% through 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Morphine 5.3.2. Codeine 5.3.3. Fentanyl 5.3.4. Meperidine 5.3.5. Methadone 5.3.6. Tramadol 5.3.7. Oxycodone 5.3.8. Dextromethorphan 5.3.9. Buprenorphine 5.3.10. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 6.3.1. Surgical Pain 6.3.2. Cancer Pain 6.3.3. Neuropathic Pain 6.3.4. Other 6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Administration, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Administration, 2023 to 2033 7.3.1. Oral 7.3.2. Parenteral 7.3.3. Transdermal 7.3.4. Other 7.4. Y-o-Y Growth Trend Analysis By Administration, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Administration, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 8.3.1. Hospitals 8.3.2. Retail Pharmacies 8.3.3. Drug Stores 8.3.4. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. U.S. 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Indication 10.2.4. By Administration 10.2.5. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Indication 10.3.4. By Administration 10.3.5. By End User 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Indication 11.2.4. By Administration 11.2.5. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Indication 11.3.4. By Administration 11.3.5. By End User 11.4. Key Takeaways 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. U.K. 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Drug Class 12.2.3. By Indication 12.2.4. By Administration 12.2.5. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Indication 12.3.4. By Administration 12.3.5. By End User 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Drug Class 13.2.3. By Indication 13.2.4. By Administration 13.2.5. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Administration 13.3.5. By End User 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Drug Class 14.2.3. By Indication 14.2.4. By Administration 14.2.5. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Indication 14.3.4. By Administration 14.3.5. By End User 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Drug Class 15.2.3. By Indication 15.2.4. By Administration 15.2.5. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Administration 15.3.5. By End User 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Indication 16.2.4. By Administration 16.2.5. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Indication 16.3.4. By Administration 16.3.5. By End User 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. U.S. 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Indication 17.1.2.3. By Administration 17.1.2.4. By End User 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Indication 17.2.2.3. By Administration 17.2.2.4. By End User 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Indication 17.3.2.3. By Administration 17.3.2.4. By End User 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Indication 17.4.2.3. By Administration 17.4.2.4. By End User 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Indication 17.5.2.3. By Administration 17.5.2.4. By End User 17.6. U.K. 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Indication 17.6.2.3. By Administration 17.6.2.4. By End User 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Indication 17.7.2.3. By Administration 17.7.2.4. By End User 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Indication 17.8.2.3. By Administration 17.8.2.4. By End User 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Indication 17.9.2.3. By Administration 17.9.2.4. By End User 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Indication 17.10.2.3. By Administration 17.10.2.4. By End User 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Indication 17.11.2.3. By Administration 17.11.2.4. By End User 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Indication 17.12.2.3. By Administration 17.12.2.4. By End User 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Indication 17.13.2.3. By Administration 17.13.2.4. By End User 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Indication 17.14.2.3. By Administration 17.14.2.4. By End User 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Indication 17.15.2.3. By Administration 17.15.2.4. By End User 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Indication 17.16.2.3. By Administration 17.16.2.4. By End User 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Indication 17.17.2.3. By Administration 17.17.2.4. By End User 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Indication 17.18.2.3. By Administration 17.18.2.4. By End User 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Indication 17.19.2.3. By Administration 17.19.2.4. By End User 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Indication 17.20.2.3. By Administration 17.20.2.4. By End User 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Indication 17.21.2.3. By Administration 17.21.2.4. By End User 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2022 17.22.2.1. By Drug Class 17.22.2.2. By Indication 17.22.2.3. By Administration 17.22.2.4. By End User 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2022 17.23.2.1. By Drug Class 17.23.2.2. By Indication 17.23.2.3. By Administration 17.23.2.4. By End User 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Indication 18.3.4. By Administration 18.3.5. By End User 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Pfizer Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Abbott Laboratories 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Janssen Pharmaceuticals, Inc. [Johnson & Johnson] 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Novartis AG 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Bayer AG 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. GlaxoSmithKline plc 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. F. Hoffmann-La Roche AG, 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Boehringer Ingelheim International GmbH 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Bausch Health Companies Inc. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Sanofi S.A. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Opioid Analgesics Market
